BioXcel Therapeutics Reports Department Of Defense Grant To University Of North Carolina To Fund Study Of BXCL501; Phase 2a Efficacy And Safety Trial Enrollment Initiation Expected In H1 2025
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics announced that the Department of Defense has granted funds to the University of North Carolina to study BXCL501. The Phase 2a trial for efficacy and safety is expected to begin enrollment in the first half of 2025.
October 15, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics received a Department of Defense grant for a study on BXCL501, with a Phase 2a trial set to start enrollment in H1 2025.
The grant from the Department of Defense to study BXCL501 is a positive development for BioXcel Therapeutics, as it supports further research and potential future approval of the drug. The initiation of a Phase 2a trial indicates progress in the drug's development pipeline, which is likely to be viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90